Kura Oncology, Inc. $KURA Shares Acquired by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. increased its stake in Kura Oncology by 13.5%, holding 338,859 shares valued at approximately $2.24 million after purchasing an additional 40,197 shares.
• Kura Oncology reported a loss of $0.75 per share in its latest quarterly results, which missed analyst estimates by $0.90, with actual revenues falling significantly short of expectations at $15.29 million.
• Analysts have mixed ratings for Kura Oncology, with a general consensus rating of "Moderate Buy" and an average price target of $24.10.

Russell Investments Group Ltd. boosted its stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 13.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 338,859 shares of the company's stock after acquiring an additional 40,197 shares during the period. Russell Investments Group Ltd. owned about 0.39% of Kura Oncology worth $2,236,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Nuveen LLC purchased a new stake in Kura Oncology in the first quarter valued at $1,564,000. Invesco Ltd. lifted its position in Kura Oncology by 44.6% in the first quarter. Invesco Ltd. now owns 97,216 shares of the company's stock valued at $642,000 after acquiring an additional 29,978 shares during the last quarter. Vanguard Group Inc. lifted its position in Kura Oncology by 2.7% in the first quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company's stock valued at $32,658,000 after acquiring an additional 129,337 shares during the last quarter. US Bancorp DE lifted its position in Kura Oncology by 79.3% in the first quarter. US Bancorp DE now owns 39,627 shares of the company's stock valued at $262,000 after acquiring an additional 17,523 shares during the last quarter. Finally, XTX Topco Ltd lifted its position in Kura Oncology by 115.1% in the first quarter. XTX Topco Ltd now owns 44,455 shares of the company's stock valued at $293,000 after acquiring an additional 23,786 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Mizuho reduced their target price on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, May 19th. Barclays reduced their target price on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Wedbush reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Kura Oncology in a report on Friday, June 20th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Kura Oncology in a report on Thursday, June 26th. Finally, JMP Securities reduced their target price on shares of Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating for the company in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $24.10.

Kura Oncology Price Performance

Shares of KURA stock traded up $0.21 during trading hours on Thursday, hitting $8.07. The company's stock had a trading volume of 3,056,920 shares, compared to its average volume of 1,837,507. The business has a fifty day moving average of $6.39 and a 200-day moving average of $6.59. The stock has a market cap of $700.48 million, a price-to-earnings ratio of -3.57 and a beta of 0.41. Kura Oncology, Inc. has a twelve month low of $5.41 and a twelve month high of $21.57. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of $0.15 by ($0.90). The firm had revenue of $15.29 million for the quarter, compared to analyst estimates of $64.95 million. As a group, equities research analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.